Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
COMPASS Pathways Plc - American Depository Shares
(NQ:
CMPS
)
6.390
+0.120 (+1.91%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about COMPASS Pathways Plc - American Depository Shares
< Previous
1
2
3
4
5
6
7
8
9
...
27
28
Next >
Compass Pathways Plc (CMPS) Q1 2024 Earnings Call Transcript
May 09, 2024
CMPS earnings call for the period ending March 31, 2024.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
CMPS Stock Earnings: Compass Pathways Misses EPS for Q1 2024
May 08, 2024
CMPS stock results show that Compass Pathways missed analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Clinical-Stage BioTech Drug Stocks Portfolio Jumped 7% In First Week Of May
May 05, 2024
We look at the performance of 10 clinical-stage AI-powered and psychedelic compound-based small cap drug discovery companies during the first week of May and YTD.
Via
Talk Markets
Jim Cramer Slams Political Blocking Of 'LSD-Derived Antidepressants,' Citing Strong Test Data 'Showing They Worked'
April 19, 2024
Via
Benzinga
Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
April 17, 2024
Via
Benzinga
Earnings Scheduled For February 29, 2024
February 29, 2024
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million.
Via
Benzinga
Earnings Preview For Compass Pathways
February 28, 2024
Via
Benzinga
Who's Who In Cannabis: Latest Executive Changes You Should Know About
April 15, 2024
Via
Benzinga
The 10 Stocks In The Clinical-Stage BioTech Drug Stocks Index Are Down 4% YTD
April 15, 2024
The pharmaceutical industry is embracing AI to streamline drug discovery and researching the use of psychedelic compound-based ingredients for the treatment of, as yet, untreatable diseases.
Via
Talk Markets
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Largest Psychedelic Drug Stocks Up Another 10% Last Week; Now Up 54% YTD
April 12, 2024
The 5 constituents in the Psychedelic Compound-Based Drug Stocks Index were up 10.0%, on average, last week and are now up 53.9% YTD.
Via
Talk Markets
Micron, Iris Energy, Trip.com Group And Other Big Stocks Moving Higher On Monday
April 01, 2024
U.S. stocks were lower, with the Dow Jones falling around 250 points on Monday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
March Recap: Largest Psychedelic Drug Stocks Up Another 5%
March 30, 2024
The 5 constituents in the munKNEE Psychedelic Compound-Based Drug Stocks Index were UP 5.4%, on average, in March and are now UP 39.9% YTD.
Via
Talk Markets
Psychedelics Headlines: A Form Of Life, Treating Chronic Pain, Microdosing And More
March 30, 2024
Via
Benzinga
Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence
March 29, 2024
Via
Benzinga
Atai Life Sciences Q4 And Full-Year 2023 Results: Steep Cash Drain Yet 2026 Target Remains, Update On Psychedelic Pipeline
March 29, 2024
Via
Benzinga
Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More
March 20, 2024
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
The Next Great Biotech Boom Has Arrived
March 19, 2024
EQNX::TICKER_START (NYSE:JNJ),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:ATAI),(NYSE:ABBV) EQNX::TICKER_END
Via
FinancialNewsMedia
FDA Grants Cybin Breakthrough Therapy Status For Major Depression Psilocybin Therapy, Company Announces Positive Clinical Data & Canadian $150M Private Placement
March 13, 2024
Via
Benzinga
Exposures
Product Safety
Psychedelic Compound-Based Drug Stock, Mind Medicine, Up 56% Last Week
March 11, 2024
The FDA has granted breakthrough designation to Mind Medicine's program for the treatment of generalized anxiety disorder.
Via
Talk Markets
Exposures
Product Safety
MindMed Receives FDA 'Breakthrough Therapy' Designation For LSD As Anxiety Treatment, Shares Positive Results About Related Clinical Trials
March 07, 2024
Via
Benzinga
Exposures
Product Safety
Psychedelics 2024: Veterans Blessing, Mental Health Paradigm Shift, Providers Training, Ketamine-MDMA Bonds & More
March 06, 2024
Via
Benzinga
3 Biopharma Stocks You Don't Want to Miss in the New Bull Market
March 05, 2024
All three have exciting programs on the way.
Via
The Motley Fool
Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More
March 04, 2024
Via
Benzinga
Largest Psychedelic Compound-Based Drug Stocks Up 15% In February; Now Up 33% YTD
March 01, 2024
The Psychedelic Compound-Based Drug Stocks Index was up 15.0% in February led by Incannex Healthcare which was up 55.1%.
Via
Talk Markets
Compass Pathways Plc (CMPS) Q4 2023 Earnings Call Transcript
February 29, 2024
CMPS earnings call for the period ending December 31, 2023.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Compass Pathways Shows Robust 2023 Year-End Results, Embraces Clinical Milestones For Psilocybin As Depression Treatment
February 29, 2024
Via
Benzinga
Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
February 29, 2024
Shares of Butterfly Network, Inc. (NASDAQ: BFLY) fell sharply during Thursday’s session after the company reported mixed fourth-quarter financial results.
Via
Benzinga
Podcast - Post-Frenzy Psychedelics Investing And Reclaiming The Right To Pursue Happiness With Zappy Zapolin: '2024 Is When It Goes Mainstream'
February 29, 2024
Via
Benzinga
Penny Power Players: 3 Stocks to Watch in the Microcap Arena
February 27, 2024
Dive into three microcap stocks set to skyrocket with innovative strategies and sector leadership. Don't miss out.
Via
InvestorPlace
Mental Health Mavericks: 3 Stocks Changing the Game
February 21, 2024
Except for the psychedelics movement, there seem to be very few mental health stocks to buy that are making money.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
7
8
9
...
27
28
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.